Active Implants SUN Clinical Trial for Persistent Knee Pain Now Underway in San Diego

UltraSight Raises $13 million to Bring AI Guidance for Cardiac Ultrasound to Patient Point of Care

The Yozma Group Korea, Atain Specialty Insurance Company and the Weizmann Institute of Science participated in the round.

Jon Hopkins New Senior Vice President-Chief Development Officer of Legion Healthcare Partners

Over the past 23 years, Jon has held various positions at Varian Medical Systems including Director of Sales, Americas West & Latin America, Varian Proton Solutions and prior Director of Worldwide Sales, Varian Particle Therapy.

Sinan Batman Appointed CTO of TeraRecon

Batman brings rich industry experience to TeraRecon, including Chief Engineer at Carestream/Kodak Health Group, where he defined the vision for image-centric workflow information systems.

Active Implants, a company that develops orthopedic implant solutions, today announced that the company’s SUN (Safety Using NUsurface®) trial is now underway in San Diego. Dr. Scott A. Hacker at Grossmont Orthopaedic Medical Group is the only physician in San Diego County – and the center is one of just 10 sites nationwide – participating in the SUN clinical trial to evaluate the investigational NUsurface Meniscus Implant (pronounced “new surface”) for the treatment of persistent knee pain caused by injured or deteriorating meniscus cartilage.

The meniscus is a tissue pad between the thigh and shin bones. Once damaged, the meniscus has a very limited ability to heal. Over 1 million partial meniscectomies to remove or repair a torn meniscus are performed in the U.S. every year, about the same as the total number of hip and knee replacement surgeries combined. However, many patients still experience persistent knee pain following meniscus surgery.

Dr. Hacker said.  “Current treatments for meniscus-related chronic knee pain do not address the underlying biology of the knee pain.” He added, “Injections and medications do provide temporary relief for some patients but are just masking the symptoms. We hope this study finds that the NUsurface implant addresses the underlying problem and gets rid of the discomfort, allowing patients to return to the leisure and work activities that had been hindered by pain.”

The SUN study will enroll approximately 120 patients as part of regulatory process to gain approval from FDA to sell the device in the U.S. All patients who meet study requirements and agree to enter the trial are offered the NUsurface Meniscus Implant as treatment. Treatment with NUsurface in the SUN trial is eligible for coverage by Medicare and some private insurance companies. To be eligible for the study, participants must be between the ages of 30 and 75 and have pain after medial meniscus surgery that was performed at least six months ago.

Learn more about the SUN study, please visit http://sun-trial.com.

spot_img

DON'T MISS

Subscribe to Medical Device News Magazine here.

Related Articles